Search results
Results from the WOW.Com Content Network
Affecting an estimated one-third of the population, insomnia can lead to significant short- and long-term health effects. Insomnia isn't just about fatigue; it can increase the risk of chronic ...
Sleep is necessary to repair cellular damage caused by reactive oxygen species and DNA damage. During long-term sleep deprivation, cellular damage aggregates up to a tipping point that triggers cellular degeneration and apoptosis.
After identifying the possible underlying causes and the factors contributing to insomnia, the person can begin taking steps towards getting better sleep. In CBT-I these steps include stimulus control, sleep hygiene, sleep restriction, relaxation training, and cognitive therapy. Some sleep specialists recommend biofeedback as well. [2]
Insomnia can be short term, lasting for days or weeks, or long term, lasting more than a month. [1] The concept of the word insomnia has two distinct possibilities: insomnia disorder (ID) or insomnia symptoms, and many abstracts of randomized controlled trials and systematic reviews often underreport on which of these two possibilities the word ...
Sleep diary layout example. Sleep medicine is a medical specialty or subspecialty devoted to the diagnosis and therapy of sleep disturbances and disorders. [1] From the middle of the 20th century, research has provided increasing knowledge of, and answered many questions about, sleep–wake functioning. [2]
When a person struggles to fall asleep or stay asleep with no obvious cause , it is referred to as insomnia, [2] which is the most common sleep disorder. [3] Others include sleep apnea , narcolepsy and hypersomnia (excessive sleepiness at inappropriate times), sleeping sickness (disruption of sleep cycle due to infection), sleepwalking , and ...
Quotes for when you're sick of counting sheep.
In 2005, ramelteon (trade name Rozerem) was the first melatonin agonist to be approved in the United States (US), indicated for insomnia treatment in adults. [58] Melatonin in the form of prolonged release (trade name Circadin ) was approved in 2007 in Europe (EU) for use as a short-term treatment, in patients 55 years and older, for primary ...